Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin
Authors:
- Xuemin ZhengXZXuemin Zheng
- Zhenghong CaoZCZhenghong Cao
- Weiren XuWXWeiren Xu
- Jianning ZhangJZJianning Zhang
- Min GongMGMin Gong
- 1 September 2012
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 434 (1-2) , 209-214
Abstract
No abstract availableKeywords
Funding Information
- Major State Basic Research Development Program of China (2010CB735602, 2010CB35600)
- Creative Research Groups of China (2011ZX09401-009)
This publication has 22 references indexed in Scilit:
- Intracellular Delivery: Exploiting Viral Membranotropic PeptidesCurrent Drug Metabolism, 2012
- Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micellesNanotechnology, 2011
- Poly(ɛ-caprolactone)–poly(ethylene glycol)–poly(ɛ-caprolactone) (PCL–PEG–PCL) nanoparticles for honokiol delivery in vitroInternational Journal of Pharmaceutics, 2009
- A New Potent Secondary Amphipathic Cell–penetrating Peptide for siRNA Delivery Into Mammalian CellsMolecular Therapy, 2009
- Peptide-Based Nanoparticle for Ex Vivo and In Vivo Dug DeliveryCurrent Pharmaceutical Design, 2008
- Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?Journal of Controlled Release, 2007
- Pros and Cons of the Liposome Platform in Cancer Drug TargetingJournal of Liposome Research, 2006
- Amphipathic peptides and drug deliveryPeptide Science, 2004
- A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA ComplexJapanese Journal of Cancer Research, 1998
- Adriamycin—A ReviewJNCI: Journal of the National Cancer Institute, 1975